Thrombolysis in acute ischaemic stroke: time for a rethink?

As the UK regulator reviews alteplase in ischaemic stroke, Brian Alper and colleagues interpret the evidence to suggest increased mortality with uncertain benefit for its use beyond three hours

Saved in:

Bibliographic Details
Published in	BMJ (Online) Vol. 350; no. mar17 3; p. h1075
Main Authors	Alper, Brian S, Malone-Moses, Meghan, McLellan, James S, Prasad, Kameshwar, Manheimer, Eric
Format	Journal Article
Language	English
Published	England British Medical Journal Publishing Group 17.03.2015 BMJ Publishing Group LTD
Subjects	ANALYSIS Associations Clinical medicine Disability Drug Administration Schedule Emergency medical care Evidence-Based Medicine Fibrinolytic Agents - therapeutic use Humans Ischemia Medicine Meta-Analysis as Topic Patients Physicians Practice Guidelines as Topic Review Literature as Topic Stroke Stroke - drug therapy Thrombolytic Therapy Tissue Plasminogen Activator - therapeutic use United Kingdom > UK Australia
Online Access	Get full text
ISSN	0959-8138 1756-1833 1756-1833
DOI	10.1136/bmj.h1075

Cover

More Information
Summary:	As the UK regulator reviews alteplase in ischaemic stroke, Brian Alper and colleagues interpret the evidence to suggest increased mortality with uncertain benefit for its use beyond three hours
Bibliography:	ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 14 content type line 23
ISSN:	0959-8138 1756-1833 1756-1833
DOI:	10.1136/bmj.h1075